Search clinical trials for: VEGFR1-1084, VEGFR2-169, and gemcitabine

Total 911 results

Osaka University
Human Genome Center, Institute of Medical Science, University of Tokyo

Completed

Anti-VEGFR Vaccine Therapy in Treating Patients With Neovascular Maculopathy

Age Related Macular Degeneration | Neovascular Maculopathy

Japan
Fukushima Medical University
Human Genome Center, Institute of Medical Science, University of Tokyo

Unknown

Antiangiogenic Peptide Vaccine Therapy With Gemcitabine in Treating Patient With Pancreatic Cancer

Pancreatic Cancer

Japan
Japanese Foundation for Cancer Research
Human Genome Center, Institute of Medical Science, University of Tokyo

Completed

Safety Study of Multiple Peptide Vaccine to Esophageal Cancer

Esophageal Cancer

Japan
Tokyo University
Human Genome Center, Institute of Medical Science, University of Tokyo

Terminated

Histocompatibility Leukocyte Antigen (HLA)-A*0201 Restricted Peptide Vaccine Therapy in Patients With Breast Cancer

Breast Cancer

Japan
Tokyo University
Human Genome Center, Institute of Medical Science, University of Tokyo

Completed

Histocompatibility Leukocyte Antigen (HLA)-A*0201 Restricted Peptide Vaccine Therapy in Patients With Gastric Cancer

Gastric Cancer

Japan
Fukushima Medical University
Human Genome Center, Institute of Medical Science, University of Tokyo

Completed

Antiangiogenic Peptide Vaccine Therapy With Gemcitabine in Treating Patient With Pancreatic Cancer (Phase1/2)

Pancreatic Cancer

Japan
Tokyo University
Human Genome Center, Institute of Medical Science, University of Tokyo

Completed

Histocompatibility Leukocyte Antigen (HLA)-A*0201 Restricted Peptide Vaccine Therapy in Patients With Esophageal Cancer

Esophageal Cancer

Japan
Tokyo University
Human Genome Center, Institute of Medical Science, University of Tokyo

Unknown

Histocompatibility Leukocyte Antigen (HLA)-A*0201 Restricted Peptide Vaccine Therapy in Patients With Non-Small Cell Lung Cancer

Non Small Cell Lung Cancer

Japan
Tokyo University
Human Genome Center, Institute of Medical Science, University of Tokyo

Completed

Histocompatibility Leukocyte Antigen (HLA)-A*2402 Restricted Peptide Vaccine Therapy in Patients With Gastric Cancer

Gastric Cancer

Japan
Fukushima Medical University
Human Genome Center, Institute of Medical Science, University of Tokyo

Unknown

HLA-A*0201 Restricted Peptide Vaccine Therapy With Gemcitabine With Gemcitabine in Patient Pancreatic Cancer (Phase1)

Pancreatic Cancer

Japan
Tokyo University
Human Genome Center, Institute of Medical Science, University of Tokyo

Terminated

Histocompatibility Leukocyte Antigen (HLA)-A*2402 Restricted Peptide Vaccine Therapy in Patients With Colorectal Cancer

Colorectal Cancer | Rectal Cancer | Colon Cancer

Japan
Tokyo University
Human Genome Center, Institute of Medical Science, University of Tokyo

Terminated

Histocompatibility Leukocyte Antigen (HLA)-A*0201 Restricted Peptide Vaccine Therapy in Patients With Colorectal Cancer

Colorectal Cancer | Rectal Cancer | Colon Cancer

Japan
Fukushima Medical University
Human Genome Center, Institute of Medical Science, University of Tokyo

Completed

Peptide Vaccine Targeting to Cancer Specific Antigen Combined With Anti-angiogenic Peptide Antigen in Treating Patients With Non-small Cell Lung Cancer

Non Small Cell Lung Cancer

Japan
Fukushima Medical University
Human Genome Center, Institute of Medical Science, University of Tokyo

Completed

Multiple-Vaccine Therapy in Treating Patients With Non-small Cell Lung Cancer

Non Small Cell Lung Cancer

Japan
Tokyo University
Human Genome Center, Institute of Medical Science, University of Tokyo

Unknown

Human Leukocyte Antigen-A*2402-Restricted Tumor Vessel Specific Peptide Vaccination for Advanced Pancreatic Cancer

Pancreatic Cancer | Pancreas Neoplasms

Japan
Groupe Hospitalier Pitie-Salpetriere

Completed

Evaluation of Reporting of Vascular Endothelial Growth Factor and Vascular Endothelial Growth Factor Receptor Inhibitors Associated Cardiovascular Adverse reactioN. (VEGAN)

Vascular Diseases | Cardiac Complication

France
Wakayama Medical University
Human Genome Center, Institute of Medical Science, University of Tokyo

Completed

Gemcitabine With Antiangiogenic Peptide Vaccine Therapy in Patients With Pancreatic Cancer

Pancreatic Cancer

Japan
Fukushima Medical University
Human Genome Center, Institute of Medical Science, University of Tokyo

Unknown

Antiangiogenic Peptide Vaccine Therapy in Treating Patient With Hepatocellular Carcinoma

Hepatocellular Carcinoma

Japan
Teikyo University
Human Genome Center, Institute of Medical Science, University of Tokyo

Unknown

Combination of Chemoradiation Therapy and Epitope Peptide Vaccine Therapy in Treating Patients With Esophageal Cancer

Esophageal Cancer

Japan
Sichuan University

Recruiting

Dual-targeting VEGFR1 and PD-L1 CAR-T for Cancers Patients With Pleural or Peritoneal Metastases

Malignant Ascites | Malignant Peritoneal Effusion | Serous Cavity Metastatises

China
Henlix, Inc

Terminated

A Study of HLX06, a Humanized Monoclonal Antibody Targeting Human Vascular Endothelial Growth Factor Receptor-2 in Patients With Advanced Solid Tumors

Solid Tumor, Adult

Taiwan
Tokyo University
Human Genome Center, Institute of Medical Science, University of Tokyo

Terminated

Human Leukocyte Antigen-A*02:01-restricted Tumor Vessel Specific Peptide Vaccination for Advanced Pancreatic Cancer

Pancreatic Cancer | Pancreas Neoplasms

Japan
City of Hope Medical Center
National Cancer Institute (NCI)

Active, not recruiting

Cellular Immunotherapy in Treating Patients With High-Risk Acute Lymphoblastic Leukemia

B Acute Lymphoblastic Leukemia | Recurrent Acute Lymphoblastic Leukemia | Refractory Acute Lymphoblastic Leukemia

United States
Fudan University
LinkDoc Technology (Beijing) Co. Ltd.

Recruiting

Effect of Huaier Granule on Nephrotoxicity Associated With Targeted Therapy for Advanced Hepatobiliary Malignancies.

Nephrotoxicity

China
Memorial Sloan Kettering Cancer Center
Juno Therapeutics, Inc.

Active, not recruiting

A Trial of "Armored" CAR T Cells Targeting CD19 For Patients With Relapsed CD19+ Hematologic Malignancies

Chronic Lymphocytic Leukemia (CLL) | Refractory | Relapsed

United States
Huabo Biopharm Co., Ltd.

Recruiting

A Study of Injection HB0025 in Patients With Advanced Solid Tumors

Tumor, Subjects

United States, China
Diabetes Foundation, India
Indian Council of Medical Research

Completed

To Study the Effects of Mango Ingestion in T2DM and Non-diabetic Subjects.

T2DM (Type 2 Diabetes Mellitus) | Normoglycemia

India
Shanghai Pulmonary Hospital, Shanghai, China

Unknown

EGFR-TKI With/Without Chemotherapy in NSCLC Patients With Both EGFR Mutation and BIM Deletion Polymorphism

Nonsmall Cell Lung Cancer | EGFR Gene Mutation
Peter Siesjö
Skane University Hospital; Lantmannen Medical AB

Recruiting

Antisecretory Factor In Severe Traumatic Brain Injury (AFISTBI)

Traumatic Brain Injury

Sweden
Huabo Biopharm Co., Ltd.

Recruiting

A Study of HB0025 Injection in Patients With Advanced Renal Cancer

Renal Cancer

China
National Cancer Institute (NCI)

Completed

Bevacizumab and Gemcitabine in Treating Patients With Advanced Pancreatic Cancer

Adenocarcinoma of the Pancreas | Recurrent Pancreatic Cancer | Stage III Pancreatic Cancer | Stage IV Pancreatic Cancer

United States
Immuneering Corporation

Recruiting

A Phase 1/2a Study of IMM-1-104 in Participants With Previously Treated, RAS-Mutant, Advanced or Metastatic Solid Tumors

Pancreatic Adenocarcinoma | Advanced Solid Tumor | Non-small Cell Lung Cancer (NSCLC) | Malignant Melanoma (Cutaneous)

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

Modified Immune Cells (CD19 CAR T Cells) and Acalabrutinib for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma

Recurrent Mantle Cell Lymphoma | Refractory Mantle Cell Lymphoma

United States
University of California, Davis
University of California, San Francisco

Completed

ProspectiveTrial of Proton Beam Combined With Anti-VEGF Therapy for Exudative Age-related Macular Degeneration (AMD) (PBAMD2)

Exudative Age-related Macular Degeneration

United States
Vaximm GmbH
Pfizer; Merck KGaA, Darmstadt, Germany

Active, not recruiting

VXM01 Plus Avelumab Combination Study in Progressive Glioblastoma

Recurrent Glioblastoma

Germany
Zhejiang University

Unknown

Continuation of TKI With or Without Chemotherapy Beyond Gradual Progression

Non Small Cell Lung Cancer

China
City of Hope Medical Center
National Cancer Institute (NCI)

Active, not recruiting

Genetically Modified T-cell Infusion Following Peripheral Blood Stem Cell Transplant in Treating Patients With Recurrent or High-Risk Non-Hodgkin Lymphoma

Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Burkitt Lymphoma | Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Adult Diffuse Mixed Cell Lymphoma | Recurrent Adult Diffuse Small Cleaved Cell Lymphoma and other conditions

United States
University Hospital, Bordeaux

Recruiting

Treatment Pause Versus Treatment Continuation in IMDC Good or Intermediate Risk With Only One Adverse Prognostic Factor in mRCC Patients With an Objective Response at 12 Months of Treatment With PD1/ PDL1 ICIs + VEGFR-Tyrosine Kinase Inhibitors (SPICI)

Metastatic Renal Cell Carcinoma | Good or Only One Adverse Prognostic Factor Intermediate Risk Per IMDC Score

France
Beijing Dongfang Biotech Co., Ltd.
Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Not yet recruiting

JY025 is a First-line Treatment for EGFR Mutated NSCLC Phase II and III Clinical Trials of Efficacy and Safety

NSCLC
National Cancer Institute (NCI)

Completed

Gemcitabine With or Without Bevacizumab in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer

Adenocarcinoma of the Pancreas | Recurrent Pancreatic Cancer | Stage III Pancreatic Cancer | Stage IV Pancreatic Cancer | Stage II Pancreatic Cancer

United States
Pavol Jozef Safarik University

Completed

Therapeutic Effect of Sodium Selenite on Oxidative Stress in Patients With Severe Sepsis (Se-AOX)

Severe Sepsis

Slovakia
Seattle Children's Hospital

Recruiting

EGFR806 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults

Soft Tissue Sarcoma | Carcinoma | Osteosarcoma | Ewing Sarcoma | Rhabdoid Tumor | Neuroblastoma | Retinoblastoma | Rhabdomyosarcoma | Wilms Tumor | Hepatoblastoma | Synovial Sarcoma | Desmoplastic Small Round Cell Tumor | Germ Cell Tumor | Pediatric Solid Tumor | Clear Cell Sarcoma | Malignant Peripheral Nerve Sheath Tumors

United States
NCIC Clinical Trials Group
GlaxoSmithKline

Completed

MET/VEGFR2 Inhibitor GSK1363089 and Erlotinib Hydrochloride or Erlotinib Hydrochloride Alone in Locally Advanced or Metastatic NSCLC That Has Not Responded to Previous Chemotherapy

Lung Cancer

Canada
National Cancer Institute (NCI)

Completed

Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Malignant Mesothelioma

Recurrent Malignant Mesothelioma | Advanced Malignant Mesothelioma | Epithelial Mesothelioma | Sarcomatous Mesothelioma | Localized Malignant Mesothelioma

United States
Shanghai Ninth People's Hospital Affiliated to...

Recruiting

All-trans Retinoic Acid (ATRA) in the Treatment of Recurrent/Metastatic Adenoid Cystic Carcinoma of the Head and Neck (Aplus)

Adenoid Cystic Carcinoma of the Head and Neck

China
Shahid Beheshti University of Medical Sciences

Completed

Pain and Visual Outcome in Intravitreal Bevacizumab Injection (pain & visual)

Diabetic Macular Edema

Iran, Islamic Republic of
The Hashemite University

Completed

Effects of Orally Administered Thymus Vulgaris Leaves on Memory, Anxiety, Depression, and Sleep Quality in University Students: A Randomized Controlled Trial

Depression | Sleep | Anxiety | Memory Dysfunction

Jordan
M.D. Anderson Cancer Center
Eli Lilly and Company

Completed

Capecitabine, Gemcitabine, and Bevacizumab in Combination for Patients With Sarcomatoid Renal Cell Carcinoma

Kidney Cancer | Renal Cell Carcinoma

United States
Seattle Children's Hospital
The Evan Foundation; Ben Towne Center for Childhood Cancer Research

Active, not recruiting

Engineered Neuroblastoma Cellular Immunotherapy (ENCIT)-01

Neuroblastoma | Ganglioneuroblastoma

United States
National Cancer Institute (NCI)
NRG Oncology

Completed

Capecitabine, Bevacizumab, and Radiation Therapy Followed By Gemcitabine and Bevacizumab in Treating Patients With Locally Advanced Pancreatic Cancer That Cannot Be Removed By Surgery

Adenocarcinoma of the Pancreas | Stage III Pancreatic Cancer | Stage II Pancreatic Cancer

United States

Search clinical trials for: VEGFR1-1084, VEGFR2-169, and gemcitabine

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Madagascar

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations